Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$763K Buy
+3,034
New +$653K 0.47% 19
2025
Q3
$721K Buy
3,112
+153
+5% +$31.2K 0.43% 23
2025
Q2
$549K Buy
2,959
+4
+0.1% +$743 0.34% 22
2025
Q1
$619K Buy
2,955
+18
+0.6% +$3.5K 0.56% 17
2024
Q4
$522K Sell
2,937
-3
-0.1% -$552 0.43% 24
2024
Q3
$558K Buy
2,940
+13
+0.4% +$2.43K 0.36% 23
2024
Q2
$497K Buy
2,927
+3
+0.1% +$497 0.37% 23
2024
Q1
$533K Buy
2,924
+2
+0.1% +$345 0.44% 22
2023
Q4
$453K Buy
+2,922
New +$426K 0.45% 24

Other funds holding ABBV

Gimbal Financial's ABBV Position: Q2 2026 in Review

Gimbal Financial opened a new position in AbbVie (ABBV) in Q2 2026: 3,034 shares worth $763K. The stake represents 0.47% of the portfolio and ranks #19 among its holdings. This is a return to the name: Gimbal Financial previously reported a position in ABBV as recently as Q3 2025.

Gimbal Financial first reported a position in ABBV in Q4 2023 and has held it in 9 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Gimbal Financial held 3,034 shares of AbbVie worth $763K as of Q2 2026.
  • AbbVie was a new Gimbal Financial position in Q2 2026.
  • AbbVie made up 0.47% of Gimbal Financial's portfolio in Q2 2026, its #19 holding.
  • Gimbal Financial first reported a position in AbbVie in Q4 2023 and has held it in 9 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Gimbal Financial's 13F filing for Q2 2026, filed 4 Aug 2026.